Abemaciclib is an oral, highly selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6).It induces cell-cycle arrest in G1 phase and inhibits proliferation in HR+/HER2- breast cancer cells.Compared with other CDK4/6 inhibitors, it can be used as monotherapy in certain settings.
Approved Indications
HR-positive, HER2-negative advanced or metastatic breast cancer
Used in combination with:
Aromatase inhibitors
Fulvestrant
Also approved as single agent in heavily pre-treated patients
Key Features
Highly selective CDK4/6 inhibition
Can be administered twice daily
Approved both in combination and as monotherapy
Strong clinical data in advanced breast cancer
Applications
API, intermediates, reference standards for R&D, generic registration and commercial manufacturing.
ECROBOT CO., Ltd, Business Registration Number : 220-88-71747, CEO J.W.Park, TEL : +82-2-552-7676, E-mail : E-mail : Contact us Address : (Hwanghwa B/D 11F, Yeoksam-dong)320, Gangnam-daero, Gangnam-gu, Seoul, South Korea
China [CN] 
Click enlarge Image